Eli Lilly and Company

Applied Molecular Evolution

Mentrik Biotech, LLC

Barrett Allan

Jirong Lu

Ying Tang

Robert Jan Benschop

Ling Liu

Ryan James Darling

Jeffry Dean Watkins

Julian Davies

Derrick Ryan Witcher

Pia Pauliina Yachi

Mark Geoffrey Chambers

Chi-Kin Chow

Jonathan Wendell Tetreault

Kristine Kay Kikly

David Matthew Marquis

Donmienne Doen Mun Leung

Andrew L Glasebrook

Lihua Huang

Sheng-Hung Rainbow Tschang

Jeffrey Streetman Boyles

Songqing Na

Andrew Charles Vendel

Kingman Ng

Hector Aldaz

Kira Vladimirovna Rubtsova

Weidong Jiang

Guifeng Zhang

Alison Lee Sim Budelsky

Brian Ondek

Andrew Gordon Werner

Donmienne Doen Leung

Andrew Lawrence Glasebrook

The present disclosure relates to antibodies that bind human CD19 ('anti-human CD19 antibodies' or 'anti-human CD19 antibodies'), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.

Anti-human CD19 antibodies

Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sj&#xf6;gren's Syndrome.

Anti-CD20&#x2212; / anti-BAFF bispecific antibodies

Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sj&#xf6;gren's Syndrome (pSS), or Multiple Myeloma (MM).

Anti-BAFF-anti-IL-17 bispecific antibodies

The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Method to treat migraines using CGRP antibodies

Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF&#x3b1;) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).

Anti-TNF-anti-IL-17 bispecific antibodies

Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.

Multifunctional antibodies binding to EGFR and MET

CGRP antibodies

The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.

Antibodies to PCSK9 and uses thereof

The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

CD20 binding molecules

Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders.

Anti-IL-17 antibodies

The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.

Variant Fc regions

Growing community of inventors

Encinitas, CA, United States of America

Barrett Allan